Poonglim Pharmatech Inc.

Based in South Korea, Poonglim Pharmatech Inc. manufactures medical devices, specializing in sterile syringes, safety needles, and vials that ensure effective medication delivery and enhance patient safety. Founded in 1999 in Gunsan, South Korea, Poonglim Pharmatech Inc. is involved in producing essential medical devices.

In November 2025, the company underwent a major investment deal whereby BNW Investment and Elio Private Equity acquired an 88% majority stake for KRW 100 billion. The latest funding will facilitate the exclusive distribution of prefilled syringe products from SCHOTT, a specialty glass manufacturer. Poonglim Pharmatech Inc. specializes in manufacturing and supplying medical devices, notably sterile syringes, safety needles, and vials, crucial for pharmaceutical companies and healthcare facilities.

The company focuses on low dead volume (LDV) syringes which improve medication delivery efficiency and enhance patient safety. Its products comply with quality standards set by the Korea Ministry of Food and Drug Safety (MFDS), ISO 13485, and the FDA, serving both domestic and international markets including regions like the Middle East and Central Asia. Poonglim Pharmatech generates revenue through direct business transactions with healthcare institutions and pharmaceutical companies. Its revenue model is based on the supply of LDV sterile syringes and EZ-Injec safety needles, sold under standard contracts or procurement agreements.

The pricing structure accommodates bulk orders, ensuring consistent revenue generation from ongoing supply needs, solidifying the company's position in the medical device market. Poonglim Pharmatech Inc. plans to leverage its recent acquisition to enhance its product offerings, particularly focusing on launching prefilled syringes in collaboration with SCHOTT by the end of 2025. The company is also targeting expansion into new markets, specifically aiming to strengthen its presence in the Middle East and Central Asia over the next several years, utilizing funding from its most recent acquisition to support these initiatives.